ELVN · Enliven Therapeutics, Inc.
$60.50
-0.37 (-0.60%)
At close · Aug 27
Market Cap
$4.43B
Shares
73.27M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$103.69M
-16.5%
FY2025
Diluted EPS
-$1.83
+3.2%
FY2025
Operating Cash Flow
-$70.3M
+3.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $89.15M | $85.86M | $80.78M | $64.57M | $31.02M | $38.44M | $32.15M | $19.01M | |
| $35.26M | $33.8M | $23.78M | $18.96M | $7.77M | $13M | $9.54M | $5.11M | |
| $166K | $300K | $300K | $300K | $200K | $100K | — | — | |
| $124.41M | $119.66M | $104.55M | $83.53M | $38.79M | $51.44M | $41.7M | $24.12M | |
| -$124.41M | -$119.66M | -$104.55M | -$83.53M | -$38.79M | -$51.44M | -$41.7M | -$24.12M | |
| $18.49M | $15.96M | $15.53M | $11.95M | $1.13M | $58K | $338K | $653K | |
| — | — | — | — | $1.58M | -$51.38M | — | — | |
| — | $0 | $232K | $0 | $0 | — | — | — | |
| -$105.93M | -$103.69M | -$89.02M | -$71.58M | -$37.66M | -$51.38M | -$41.36M | -$23.46M | |
| -$107.66M | -$103.42M | -$89.11M | -$71.44M | -$37.66M | -$51.4M | -$41.39M | -$23.43M | |
| USD/shares | -$1.64 | -$1.83 | -$1.89 | -$2.01 | -$12.05 | -$2.37 | — | — |
| USD/shares | -$1.64 | -$1.83 | -$1.89 | -$2.01 | -$12.05 | -$2.37 | — | — |
| shares | — | 56.66M | 47.07M | 35.55M | 3.12M | 21.66M | 13.92M | 702.46K |
| shares | — | 56.66M | 47.07M | 35.55M | 3.12M | 21.66M | 13.92M | 702.46K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.98×
EV/EBIT
—
Peer median 23.64×
P/E (TTM)
—
Peer median 18.98×
Peer medians compare against the 203 similar-size Biotechnology companies (of 534 listed).
Key facts
CIK
1672619
CUSIP
29337E102
13F (30d)
195 filings
194 filers
Visit website
Investor relations